Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

359

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Asthma
Interventions
DRUG

FF/VI

FF/VI will be administered.

DRUG

FF/UMEC/VI

FF/UMEC/VI will be administered.

DEVICE

ELLIPTA

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.

Trial Locations (61)

30000

GSK Investigational Site, Taiyuan

66000

GSK Investigational Site, Qinhuangdao

100020

GSK Investigational Site, Beijing

110000

GSK Investigational Site, Shenyang

110004

GSK Investigational Site, Shenyang

130021

GSK Investigational Site, Changchun

200032

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

200090

GSK Investigational Site, Shanghai

200233

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

210006

GSK Investigational Site, Nanjing

214023

GSK Investigational Site, Wuxi

221006

GSK Investigational Site, Xuzhou

222006

GSK Investigational Site, Lianyungang

230001

GSK Investigational Site, Hefei

250012

GSK Investigational Site, Jinan

266071

GSK Investigational Site, Qingdao

300052

GSK Investigational Site, Tianjin

310005

GSK Investigational Site, Hangzhou

310006

GSK Investigational Site, Hangzhou

323027

GSK Investigational Site, Wenzhou

330038

GSK Investigational Site, Nanchang

350005

GSK Investigational Site, Fuzhou

361004

GSK Investigational Site, Xiamen

400038

GSK Investigational Site, Chongqing

410013

GSK Investigational Site, Changsha

430060

GSK Investigational Site, Wuhan

430061

GSK Investigational Site, Wuhan

450000

GSK Investigational Site, Zhengzhou

453004

GSK Investigational Site, Xinxiang

510030

GSK Investigational Site, Qingyuan

510120

GSK Investigational Site, Guangzhou

510150

GSK Investigational Site, Guangzhou

510180

GSK Investigational Site, Guangzhou

510280

GSK Investigational Site, Guangzhou

516000

GSK Investigational Site, Huizhou

518020

GSK Investigational Site, Shenzhen

518036

GSK Investigational Site, Shenzhen

518053

GSK Investigational Site, Shenzhen

523059

GSK Investigational Site, Dongguan

524001

GSK Investigational Site, Zhanjiang

524045

GSK Investigational Site, Zhanjiang

528400

GSK Investigational Site, Zhongshan

529030

GSK Investigational Site, Jiangmen

530022

GSK Investigational Site, Nanning

541001

GSK Investigational Site, Guilin

541002

GSK Investigational Site, Guilin

563114

GSK Investigational Site, Zunyi

570311

GSK Investigational Site, Sanya

610041

GSK Investigational Site, Chengdu

650051

GSK Investigational Site, Kunming

710000

GSK Investigational Site, Xi'an

730020

GSK Investigational Site, Lanzhou

750004

GSK Investigational Site, Yinchuan

830054

GSK Investigational Site, Ürümqi

Unknown

GSK Investigational Site, Chongqing

GSK Investigational Site, Sanya

010017

GSK Investigational Site, Hohhot

010050

GSK Investigational Site, Hohhot

050000

GSK Investigational Site, Shijiazhuang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY